Solara Active Pharma Sciences Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Solara Active Pharma Sciences Ltd filed with BSE on 21 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Solara reported Q4 FY26 revenue of Rs 392 crore, up 12% quarter-on-quarter, with EBITDA of Rs 61 crore, up 65% Q-o-Q, driven by the base business which operates at higher margins. The ibuprofen business continued to post negative EBITDA, and the Board has appointed bankers to evaluate strategic options for it, with a conclusion expected in H1 FY27. The company also reduced debt by roughly Rs 158 crore during FY26, aided by rights issue call money and operational cash flows.
Numbers mentioned
Revenue: INR 392 crores (Q4 FY26)
p. 3
“We delivered revenue of INR 392crs.”
Sandeep Rao, page 3 of the filed PDF · View the filing
Revenue growth Q-o-Q: 12% (Q4 FY26)
p. 3
“Revenue has a 12% Q-o-Q growth.”
Sandeep Rao, page 3 of the filed PDF · View the filing
Gross margin: 47%, INR184 crores (Q4 FY26)
p. 3
“Gross margins are at 47% with an absolute value of INR184 crores for the quarter.”
Sandeep Rao, page 3 of the filed PDF · View the filing
Gross margin improvement: 170 basis points Q-o-Q (Q4 FY26)
p. 3
“This reflects an improvement of gross margin by 170 basis points on a Q-o-Q basis.”
Sandeep Rao, page 3 of the filed PDF · View the filing
EBITDA: INR61 crores (Q4 FY26)
p. 4
“This has resulted in an EBITDA of INR61 crores, which reflects a significant Q-o-Q growth of 65%.”
Sandeep Rao, page 4 of the filed PDF · View the filing
Developed markets contribution: 75% of overall sales (Q4 FY26)
p. 4
“Business contribution from our developed markets, which is our mainstay, continues to be at 75% of overall sales.”
Sandeep Rao, page 4 of the filed PDF · View the filing
Base business EBITDA margin: 26%
p. 3
“It operates at 26% EBITDA margin with gross margins of 54%.”
Sandeep Rao, page 3 of the filed PDF · View the filing
EBITDA margin: 16% (Q4 FY26)
p. 4
“Solara business has clocked an EBITDA margin of 16% with an absolute EBITDA value of INR61 crores plus, which reflects significant growth of 65% Q-on-Q because we had quite a few subdued quarters in Q2 and Q3.”
Sarat Kumar, page 4 of the filed PDF · View the filing
Debt reduction: INR158-odd crores, 21% reduction (FY26)
p. 4
“we have been able to reduce our debt by roughly INR158-odd crores during FY26, which actually signifies close to 21% reduction in the debt during the year”
Sarat Kumar, page 4 of the filed PDF · View the filing
Rights issue first call money: INR113 crores (May '26)
p. 4
“out of which INR113 crores came off from the first call money of rights, which we had in May '26”
Sarat Kumar, page 4 of the filed PDF · View the filing
Debt repayment from operational cash flows: INR45 crores (FY26)
p. 4
“balance INR45 crores were actually paid off from our operational cash flows”
Sarat Kumar, page 4 of the filed PDF · View the filing
Capacity utilization: 70%
p. 5
“So, if you look at our capacity, we are currently using around 70% of our capacity.”
Sandeep Rao, page 5 of the filed PDF · View the filing
CRAMS annual revenue: INR10 crores - INR12 crores
p. 8
“our annual numbers from CRAMS are close to INR10 crores - INR12 crores”
Sarat Kumar, page 8 of the filed PDF · View the filing
R&D spend over past years: roughly INR200 crores (past 4-5 years)
p. 10
“So R&D is something which we have spent roughly close to INR200 crores in the past 4, 5 years.”
Sarat Kumar, page 10 of the filed PDF · View the filing
Current annual R&D spend: INR25 crores
p. 10
“Having said that, our current annual rate of spend is close to INR25 crores on R&D.”
Sarat Kumar, page 10 of the filed PDF · View the filing
Vizag facility fixed costs: INR12 crores to INR15 crores (annually)
p. 15
“we have certain fixed cost expenditure for the Vizag site which is INR12 crores to INR15 crores annually”
Sarat Kumar, page 15 of the filed PDF · View the filing
Top products revenue mix: top 15-20 products, 75% of business
p. 7
“roughly, we have commercialized close to 70 products in the entire portfolio, what we sell currently, of which roughly top 15 to 20 products has a mix of close to 75% of the entire business.”
Sarat Kumar, page 7 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Strategic options for ibuprofen — conclusion on strategic options · H1 FY27
stated firmly by Sandeep Rao
p. 6
“I believe we'll be in a better position to put out the conclusion on this strategic piece in H1 of this financial year.”
Sandeep Rao, page 6 of the filed PDF · View the filing
Base business EBITDA margin — 25% plus · next 2-3 years
stated as an aspiration by Sarat Kumar
p. 8
“We have been maintaining that we will be close to in the range of 25% plus, minus here and there.”
Sarat Kumar, page 8 of the filed PDF · View the filing
Company debt-free target — debt-free · FY29
stated firmly by Sarat Kumar
p. 12
“So we have an internal target of making Solara debt-free by FY '29.”
Sarat Kumar, page 12 of the filed PDF · View the filing
Further capital raise — no further capital raise
stated firmly by Sarat Kumar
p. 12
“So, after this rights issue, what has already been subscribed, we actually don't have any further plans to raise further capital either through equity or debt at this point of time.”
Sarat Kumar, page 12 of the filed PDF · View the filing
DMF filings — four to five DMF filings per year · starting FY27
stated firmly by Sandeep Rao
p. 10
“So we have a plan to do four to five DMF filings every year to start.”
Sandeep Rao, page 10 of the filed PDF · View the filing
Impact of new R&D products — FY29, FY30 onwards
stated as an aspiration by Sandeep Rao
p. 11
“But all this will start seeing impactful revenues and margins coming in around the FY29, FY30 timeframe.”
Sandeep Rao, page 11 of the filed PDF · View the filing
Quarterly revenue and EBITDA outlook — FY27 and FY28
stated as an aspiration by Sandeep Rao
p. 10
“No, Harshit. We will not give any outlook at this point.”
Sandeep Rao, page 10 of the filed PDF · View the filing
Vizag facility future plan — clear roadmap · H1
stated firmly by Sarat Kumar
p. 7
“you will have to give us time till H1 by when we will have a clear road map of exactly what we do with Vizag.”
Sarat Kumar, page 7 of the filed PDF · View the filing
Base business growth rate — better than 6%
stated as an aspiration by Sandeep Rao
p. 16
“That's my goal. I want to grow that business at a better rate, which I think requires a lot of management time and resource is I'd like to invest more time in that business.”
Sandeep Rao, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the growth came from a healthy order book and utilization improvements, not one-off factors.
Answered by Sandeep Rao
Asked by Sajal Kapoor: How much of the Q4 base business improvement was structural versus temporary factors like restocking or spot orders?
p. 5
“No, no, no, Sajal. There's nothing one-off there.”
Sandeep Rao, page 5 of the filed PDF · View the filing
Management said the company is using about 70% of capacity, with additional gains from debottlenecking projects.
Answered by Sandeep Rao
Asked by Sajal Kapoor: How much spare capacity exists to drive incremental margins without new fixed costs?
p. 5
“So, the story here is very clear. We want to keep our opex base minimal, and we have to increase year-on-year.”
Sandeep Rao, page 5 of the filed PDF · View the filing
Management said the process is ongoing with bankers appointed, and a conclusion is expected in H1.
Answered by Sandeep Rao
Asked by Pranav Chawla: What strategic options are being evaluated for ibuprofen and why hasn't an update come sooner?
p. 6
“In fact, we've mentioned in our report out that we've appointed bankers to sort of give us strategic advice on this.”
Sandeep Rao, page 6 of the filed PDF · View the filing
Management confirmed the company sources its starting material, IBAP, from third parties and is not backward integrated.
Answered by Sarat Kumar
Asked by Pranav Chawla: Is Solara backward integrated in ibuprofen manufacturing?
p. 6
“Our starting material is IBAP. So, we are absolutely not backward integrated by any means.”
Sarat Kumar, page 6 of the filed PDF · View the filing
Management said the plant was commissioned in 2024 but has been mothballed, with a decision on its future to come after the ibuprofen strategic review.
Answered by Sarat Kumar
Asked by Ankur Bhadekar: What is the status of the Vizag facility commissioning timeline mentioned in the previous call?
p. 7
“As compared to what you say, Vizag plant commissioning has been actually done long back in 2024. But however, from 2024, the site has been mothballed.”
Sarat Kumar, page 7 of the filed PDF · View the filing
Management said no single molecule drives most revenue, with the top 15-20 products making up about 75% of the business.
Answered by Sarat Kumar
Asked by Dhruv Sitlani: What is the product concentration in the base API business?
p. 7
“So, we actually don't have a single molecule or single product driving most of the growth.”
Sarat Kumar, page 7 of the filed PDF · View the filing
Management said options include finding a buyer or converting to a multi-product facility, with priority given to finding a qualified buyer.
Answered by Sandeep Rao
Asked by Prolin Nandu: What are the strategic options being considered for ibuprofen and what has changed since last quarter?
p. 9
“I think there, there is a priority, right, in the sense that if we do find a qualified buyer for this business, that probably would be option number 1.”
Sandeep Rao, page 9 of the filed PDF · View the filing
Management declined to give guidance, focusing instead on sequential improvement.
Answered by Sandeep Rao
Asked by Harshit Khadka: What revenue and EBITDA outlook can be expected for FY27 and FY28?
p. 10
“But at this point in time, my priority and my team's priority is going to be just dig our heels in here and try to do better quarter-over-quarter.”
Sandeep Rao, page 10 of the filed PDF · View the filing
Management said current annual R&D spend is about Rs 25 crore, with a revived pipeline focused on commercial filings starting late FY26.
Answered by Sarat Kumar
Asked by Amlan Chakraborty: How much is Solara spending on R&D for its API business?
p. 10
“So although we have spent our efforts on R&D, we have not been able to have success from those particular efforts.”
Sarat Kumar, page 10 of the filed PDF · View the filing
Management said no further capital raise plans exist after the current rights issue call money.
Answered by Sarat Kumar
Asked by Rohit Koti: Does the company plan to raise more capital for growth or debt paydown?
p. 12
“So, after this rights issue, what has already been subscribed, we actually don't have any further plans to raise further capital either through equity or debt at this point of time.”
Sarat Kumar, page 12 of the filed PDF · View the filing
Management said fixed costs of Rs 12-15 crore annually are being incurred despite no revenue generation.
Answered by Sarat Kumar
Asked by Ketan R. Chheda: What expenses are being incurred on the mothballed Vizag facility?
p. 15
“Yes. So as you said, this has been mothballed since '24. However, we have certain fixed cost expenditure for the Vizag site which is INR12 crores to INR15 crores annually.”
Sarat Kumar, page 15 of the filed PDF · View the filing
Management said ibuprofen is a commodity business generating negative EBITDA and prefers to invest in the higher-margin base business.
Answered by Sandeep Rao
Asked by Ketan R. Chheda: Why not invest in backward integration or technology change for ibuprofen instead of divesting?
p. 15
“See, at the end of the day, ibuprofen is a commodity business. Right? And a business that has continuously generated negative EBITDA for us.”
Sandeep Rao, page 15 of the filed PDF · View the filing
Risks flagged
Ibuprofen business continues to generate negative EBITDA
p. 3
“On Ibuprofen, we continue to face persistent headwinds in this business where we recorded a negative EBITDA.”
Sandeep Rao, page 3 of the filed PDF · View the filing
Crisis in the Middle East impacting global business
p. 4
“Despite the significant crisis we've had in the Middle East and its impact on global business, I'd like to reiterate that the fundamentals of our base business continue to be strong.”
Sandeep Rao, page 4 of the filed PDF · View the filing
Lack of backward integration and access to new technologies in ibuprofen
p. 9
“Secondly, we also don't have access to new technologies which some of our competitors have.”
Sandeep Rao, page 9 of the filed PDF · View the filing
CRAMS business remains subscale with weak pipeline visibility
p. 8
“However, in the entire numbers, CRAMS is something which is very subscale.”
Sarat Kumar, page 8 of the filed PDF · View the filing
No meaningful new DMF filings in recent years limiting product pipeline
p. 10
“So although we have spent our efforts on R&D, we have not been able to have success from those particular efforts.”
Sarat Kumar, page 10 of the filed PDF · View the filing
Carve-out of polymers CRAMS business delayed pending ibuprofen strategic decision
p. 3
“Consequent to this, the carve-out of the polymers in the CRAMS business has put on hold until such time as we can finalize the strategic options for the ibuprofen business in H1 '27.”
Sandeep Rao, page 3 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.